Liquid Biopsy: An Emerging Diagnostic, Prognostic, and Predictive Tool in Gastric Cancer

Overview

Journal J Gastric Cancer

Date 2024 Jan 16

PMID 38225764

Authors

Hye Sook Han

Keun-Wook Lee

Affiliations

Soon will be listed here.

Abstract

Liquid biopsy, a minimally invasive procedure that causes minimal pain and complication risks to patients, has been extensively studied for cancer diagnosis and treatment. Moreover, it facilitates comprehensive quantification and serial assessment of the whole-body tumor burden. Several biosources obtained through liquid biopsy have been studied as important biomarkers for establishing early diagnosis, monitoring minimal residual disease, and predicting the prognosis and response to treatment in patients with cancer. Although the clinical application of liquid biopsy in gastric cancer is not as robust as that in other cancers, biomarker studies using liquid biopsy are being actively conducted in patients with gastric cancer. Herein, we aimed to review the role of various biosources that can be obtained from patients with gastric cancer through liquid biopsies, such as blood, saliva, gastric juice, urine, stool, peritoneal lavage fluid, and ascites, by dividing them into cellular and acellular components. In addition, we reviewed previous studies on the diagnostic, prognostic, and predictive biomarkers for gastric cancer using liquid biopsy and discussed the limitations of liquid biopsy and the challenges to overcome these limitations in patients with gastric cancer.

Citing Articles

Minimal Residual Disease in Metastatic Soft Tissue Sarcoma.

Kournoutas I, Siontis B Curr Treat Options Oncol. 2025; .

PMID: 40072823 DOI: 10.1007/s11864-025-01303-x.

Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).

Alsina Maqueda M, Teijo Quintans A, Cuatrecasas M, Fernandez Acenero M, Fernandez Montes A, Gomez Martin C Clin Transl Oncol. 2025; .

PMID: 40072752 DOI: 10.1007/s12094-025-03865-6.

Longitudinal detection of somatic mutations in the saliva of head and neck squamous cell carcinoma-affected patients: a pilot study.

Dal Secco C, Tel A, Allegri L, Baldan F, Curcio F, Sembronio S Front Oncol. 2024; 14:1480302.

PMID: 39555458 PMC: 11564150. DOI: 10.3389/fonc.2024.1480302.

Establishment of liquid biopsy procedure for the analysis of circulating cell free DNA, exosomes, RNA and proteins in colorectal cancer and adenoma patients.

ceri A, Somborac-Bacura A, Fabijanec M, Hulina-Tomaskovic A, Matusina M, Detel D Sci Rep. 2024; 14(1):26925.

PMID: 39506031 PMC: 11541997. DOI: 10.1038/s41598-024-78497-x.

Immunological Strategies in Gastric Cancer: How Toll-like Receptors 2, -3, -4, and -9 on Monocytes and Dendritic Cells Depend on Patient Factors?.

Kos M, Bojarski K, Mertowska P, Mertowski S, Tomaka P, Dziki L Cells. 2024; 13(20.

PMID: 39451226 PMC: 11506270. DOI: 10.3390/cells13201708.

References

Dong L, Qi P, Xu M, Ni S, Huang D, Xu Q . Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int J Cancer. 2015; 137(5):1128-35. DOI: 10.1002/ijc.29484. View

Cheng B, Tong G, Wu X, Cai W, Li Z, Tong Z . Enumeration And Characterization Of Circulating Tumor Cells And Its Application In Advanced Gastric Cancer. Onco Targets Ther. 2019; 12:7887-7896. PMC: 6768312. DOI: 10.2147/OTT.S223222. View

Liu J, Wang J, Song Y, Ma B, Luo J, Ni Z . A panel consisting of three novel circulating lncRNAs, is it a predictive tool for gastric cancer?. J Cell Mol Med. 2018; 22(7):3605-3613. PMC: 6010868. DOI: 10.1111/jcmm.13640. View

Hiraki M, Kitajima Y, Koga Y, Tanaka T, Nakamura J, Hashiguchi K . Aberrant gene methylation is a biomarker for the detection of cancer cells in peritoneal wash samples from advanced gastric cancer patients. Ann Surg Oncol. 2011; 18(10):3013-9. DOI: 10.1245/s10434-011-1636-0. View

Yun J, Han S, Kim H, Go S, Lee W, Bae W . Exosomal miR-181b-5p Downregulation in Ascites Serves as a Potential Diagnostic Biomarker for Gastric Cancer-associated Malignant Ascites. J Gastric Cancer. 2019; 19(3):301-314. PMC: 6769363. DOI: 10.5230/jgc.2019.19.e27. View

Dan Zeng C, Jin C, Gao C, Xiao A, Tong Y, Zhang S . Preoperative Folate Receptor-Positive Circulating Tumor Cells Are Associated With Occult Peritoneal Metastasis and Early Recurrence in Gastric Cancer Patients: A Prospective Cohort Study. Front Oncol. 2022; 12:769203. PMC: 9002093. DOI: 10.3389/fonc.2022.769203. View

Kato S, Okamura R, Baumgartner J, Patel H, Leichman L, Kelly K . Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clin Cancer Res. 2018; 24(24):6248-6256. PMC: 6384095. DOI: 10.1158/1078-0432.CCR-18-1128. View

Lee J, Kim M, Seong M, Kim H, Lee Y, Kang H . Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction. Clin Chem Lab Med. 2019; 58(4):527-532. DOI: 10.1515/cclm-2019-0896. View

Yang Z, Sun Y, Liu R, Shi Y, Ding S . Plasma long noncoding RNAs PANDAR, FOXD2-AS1, and SMARCC2 as potential novel diagnostic biomarkers for gastric cancer. Cancer Manag Res. 2019; 11:6175-6184. PMC: 6613614. DOI: 10.2147/CMAR.S201935. View

10.

Li S, Zhang M, Zhang H, Hu K, Cai C, Wang J . Exosomal long noncoding RNA lnc-GNAQ-6:1 may serve as a diagnostic marker for gastric cancer. Clin Chim Acta. 2019; 501:252-257. DOI: 10.1016/j.cca.2019.10.047. View

11.

Lone S, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S . Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022; 21(1):79. PMC: 8932066. DOI: 10.1186/s12943-022-01543-7. View

12.

Willis J, Lefterova M, Artyomenko A, Kasi P, Nakamura Y, Mody K . Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clin Cancer Res. 2019; 25(23):7035-7045. DOI: 10.1158/1078-0432.CCR-19-1324. View

13.

Pu W, Zhang R, Xiao L, Wu Y, Gong W, Lv X . Prediction of cancer progression in a group of 73 gastric cancer patients by circulating cell-free DNA. BMC Cancer. 2016; 16(1):943. PMC: 5148873. DOI: 10.1186/s12885-016-2977-7. View

14.

Okabe H, Tsunoda S, Hosogi H, Hisamori S, Tanaka E, Tanaka S . Circulating Tumor Cells as an Independent Predictor of Survival in Advanced Gastric Cancer. Ann Surg Oncol. 2015; 22(12):3954-61. DOI: 10.1245/s10434-015-4483-6. View

15.

Paschold L, Binder M . Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer. Curr Oncol. 2022; 29(3):1430-1441. PMC: 8947276. DOI: 10.3390/curroncol29030120. View

16.

Lan Y, Chen M, Fang W, Hsieh C, Lin C, Jhang F . Clinical relevance of cell-free DNA in gastrointestinal tract malignancy. Oncotarget. 2016; 8(2):3009-3017. PMC: 5356859. DOI: 10.18632/oncotarget.13821. View

17.

Ge L, Zhang N, Li D, Wu Y, Wang H, Wang J . Circulating exosomal small RNAs are promising non-invasive diagnostic biomarkers for gastric cancer. J Cell Mol Med. 2020; 24(24):14502-14513. PMC: 7753781. DOI: 10.1111/jcmm.16077. View

18.

Zong W, Feng W, Jiang Y, Ju S, Cui M, Jing R . Evaluating the diagnostic and prognostic value of serum long non-coding RNA CTC-497E21.4 in gastric cancer. Clin Chem Lab Med. 2019; 57(7):1063-1072. DOI: 10.1515/cclm-2018-0929. View

19.

Choi B, Lee H, Min J, Choe H, Choi Y, Son Y . Plasma expression of the intestinal metaplasia markers CDH17 and TFF3 in patients with gastric cancer. Cancer Biomark. 2017; 19(3):231-239. DOI: 10.3233/CBM-160147. View

20.

Zhang K, Shi H, Xi H, Wu X, Cui J, Gao Y . Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer. Theranostics. 2017; 7(1):213-227. PMC: 5196898. DOI: 10.7150/thno.16044. View